The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Chemotherapy-induced senescence, an adaptive mechanism driving resistance and tumor heterogeneity
Open accessAbstract
Senescence is activated in response to chemotherapy to prevent the propagation of cancer cells. In transformed cells, recent studies have shown that this response is not always definitive and that persistent populations can use senescence as an adaptive pathway to restart proliferation and become more aggressive. Here we discuss the results showing that an incomplete and heterogeneous senescence response plays a key role in chemotherapy resistance. Surviving to successive chemotherapy regimens, chronically existing senescent cells can create a survival niche through paracrine cooperations with neighboring cells. This favors chemotherapy escape of premalignant clones but might also allow the survival of adjacent clones presenting a lower fitness. A better characterization of senescence heterogeneity in transformed cells is therefore necessary. This will help us to understand this incomplete response to therapy and how it could generate clones with increased tumor capacity leading to disease relapse.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Crucially to our findings, incomplete and heterogeneous senescence response of cancer cells contributes to chemotherapy resistance [53].”
From Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients (2022) · cites this paper as [53]
Citations
Cites
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 2×
“[4] Serrano M, Lin AW, McCurrach ME, et al.”
BackgroundSTATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383
Tumour-associated macrophages as treatment targets in oncology
Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., & Allavena, P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.217 · Cited by 4,182
p21 in cancer: Intricate networks and multiple activities
Abbas, T., & Dutta, A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2657 · Cited by 2,712
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473
Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence
Narita, M., Nuñez, S., Heard, E., Narita, M., Lin, A. W., Hearn, S. A., Spector, D. L., Hannon, G. J., & Lowe, S. W. (2003) · Cell · doi:10.1016/s0092-8674(03)00401-x · Cited by 2,278 · cited 2×
“[10] Narita M, Nunez S, Heard E, et al.”
BackgroundA complex secretory program orchestrated by the inflammasome controls paracrine senescence
Acosta, J. C., Banito, A., Wuestefeld, T., Georgilis, A., Janich, P., Morton, J. P., Athineos, D., Kang, T.-W., Lasitschka, F., Andrulis, M., et al. (2013) · Nature Cell Biology · doi:10.1038/ncb2784 · Cited by 2,278 · cited 2×
“This secretome maintains the proliferative arrest through an autocrine loop but some of its components also transmit this suppressive signal to neighboring cells [17].”
BackgroundPersistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion
Rodier, F., Coppé, J.-P., Patil, C. K., Hoeijmakers, W. A. M., Muñoz, D. P., Raza, S. R., Freund, A., Campeau, E., Davalos, A. R., & Campisi, J. (2009) · Nature Cell Biology · doi:10.1038/ncb1909 · Cited by 2,232
BRAFE600-associated senescence-like cell cycle arrest of human naevi
Michaloglou, C., Vredeveld, L. C. W., Soengas, M. S., Denoyelle, C., Kuilman, T., van der Horst, C. M. A. M., Majoor, D. M., Shay, J. W., Mooi, W. J., & Peeper, D. S. (2005) · Nature · doi:10.1038/nature03890 · Cited by 2,160
Research works printed but not linked: 3
- 10.1016/j.cell.2008.06.049 · DOI · Paper page
- Roninson IB, 2003, Cancer Res, 63, 2705
- Georgilis A, 2018, Cancer Cell, 34, e109
Cited by
Sorted by citations
Unveiling the mechanisms and challenges of cancer drug resistance
Khan, S. U., Fatima, K., Aisha, S., & Malik, F. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-023-01302-1 · Cited by 417
Thorel, L., Perréard, M., Florent, R., Divoux, J., Coffy, S., Vincent, A., Gaggioli, C., Guasch, G., Gidrol, X., Weiswald, L.-B., et al. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01272-5 · Cited by 236
The redox-senescence axis and its therapeutic targeting
Ngoi, N. Y. L., Liew, A. Q. X., Chong, S. J. F., Davids, M. S., Clement, M., & Pervaiz, S. (2021) · Redox Biology · doi:10.1016/j.redox.2021.102032 · Cited by 94
Senescence-Associated Pro-inflammatory Cytokines and Tumor Cell Plasticity
Vernot, J. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00063 · Cited by 85
Colucci, M., Zumerle, S., Bressan, S., Gianfanti, F., Troiani, M., Valdata, A., D’Ambrosio, M., Pasquini, E., Varesi, A., Cogo, F., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.02.004 · Cited by 89
Metadata
- Authors
- Guillon, J., Petit, C., Toutain, B., Guette, C., Lelièvre, E., & Coqueret, O.
- Affiliations
- Inserm (FR)
- Corresponding author
- Coqueret, Olivier
- Venue
- Cell Cycle
- Publisher
- Informa UK Limited
- Published
- 2019-08-09
- Volume
- 18
- Issue
- 19
- Pages
- 2385-2397
- ISSN
- 1538-4101 (ISSN-L)
- 1551-4005
- PMC
- PMC6738909
- OpenAlex
- W2966996218
- Cited by
- 102
- References
- 72
- Citations by year
- 2026: 9 · 2025: 18 · 2024: 20 · 2023: 24 · 2022: 11 · 2021: 13 · 2020: 6 · 2019: 1
- FWCI
- 0.91
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cell Cycle (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Funders
- Ligue Contre le Cancer (NA)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Keywords
- chemotherapy-induced senescence, chemoresistance, tumor heterogeneity, senescence escape, paracrine signaling, recurrence, senescent cells, tumor cell proliferation
- MeSH terms
- Antineoplastic Agents, Clone Cells, Humans, Neoplasm Recurrence, Local, Neoplasms, Signal Transduction, Oncogene Proteins, Gene Expression Regulation, Neoplastic, Cellular Senescence, Apoptosis, Drug Resistance, Neoplasm, Tumor Suppressor Proteins, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
